Massive Bio Launches NexusPulse, Real-Time AI Signal Engine for Oncology

NexusPulse transforms real-world clinical and biomarker data into actionable intelligence for oncology teams.

Mar. 19, 2026 at 3:03pm

Got story updates? Submit your updates here. ›

Massive Bio has announced the launch of NexusPulse, a real-time AI signal engine that helps oncology organizations detect change earlier, prioritize the right next action, and accelerate testing, treatment, and trial access. NexusPulse continuously analyzes consented real-world clinical and biomarker data to surface high-priority biomarker and treatment opportunities and reduce signal-to-action time by over 40%.

Why it matters

NexusPulse is designed to provide oncology teams with a live view of market shifts, patient access gaps, and opportunities for action, moving from retrospective reporting to real-time activation. This aims to create a more connected and responsive oncology ecosystem by helping teams focus on the actions most likely to improve biomarker testing, therapy initiation, patient access, and trial acceleration.

The details

NexusPulse is built within Massive Bio's Reticulum Nexus platform and powered by the company's SYNERGY-AI technology. It combines real-world data, graph intelligence, configurable triggers, and AI-driven prioritization to help oncology teams detect meaningful shifts across diagnosis, biomarker testing, treatment initiation, switching, referral flow, site behavior, and patient journey friction. NexusPulse then translates these changes into prioritized alerts, opportunity maps, and next-best actions for commercial, medical, and market access teams.

  • NexusPulse was launched on March 19, 2026.

The players

Massive Bio

An AI-enabled real-world data company that transforms the pharmaceutical value chain and helps connect patients, providers, sites, and life sciences organizations across the oncology journey.

Selin Kurnaz, PhD

Cofounder and CEO of Massive Bio.

Çağatay Çulcuoğlu

Cofounder, CTO, and COO of Massive Bio.

Arturo Loaiza-Bonilla, MD

Cofounder and Chief Medical AI Officer of Massive Bio.

Got photos? Submit your photos here. ›

What they’re saying

“Oncology teams do not need more dashboards. They need faster clarity, better timing, and a direct path from insight to action.”

— Selin Kurnaz, PhD, Cofounder & CEO of Massive Bio

“NexusPulse was built for speed, precision, and execution.”

— Çağatay Çulcuoğlu, Cofounder, CTO & COO of Massive Bio

“NexusPulse is how AI listens to the pulse of real-world oncology markets, and turns that pulse into action.”

— Arturo Loaiza-Bonilla, MD, Cofounder & Chief Medical AI Officer of Massive Bio

What’s next

As part of Massive Bio's connected oncology platform ecosystem, NexusPulse will extend the capabilities of Reticulum Nexus, work alongside TrialRelay to support intelligent routing and activation, and build on the foundation of Radiant Core and SYNERGY-AI to deliver continuous signal-to-action execution.

The takeaway

NexusPulse represents a shift from retrospective reporting to real-time activation, providing oncology teams with a live view of market changes and opportunities for action. By combining real-world data, AI-driven analytics, and intelligent orchestration, NexusPulse aims to help teams detect change earlier, predict what matters next, and act with precision across testing, treatment, and trial access.